IL‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study

Abstract

AbstractBackgroundSystemic inflammation is considered a major player in the pathogenesis of epidermolysis bullosa (EB), but its pattern has only been described in small heterogeneous cohorts. There is controversy if and how systemic inflammation should be therapeutically targeted.MethodsWe examined serum proinflammatory, anti‐inflammatory, and itch related cytokines in a paediatric cohort of 29 patients with junctional and dystrophic EB. The cytokine that emerged as the most relevant was measured in a validation cohort of 42 patients during follow‐up visits over 2 years.ResultsIL‐6 showed the most consistent and highest aberration dominating systemic inflammation. IL‐6 correlated with wound body surface area (BSA) in both, finding and validation cohorts. Patients with less than 3% wound BSA had normal IL‐6, while IL‐6 levels significantly increased at more than 5% and 10% of wound BSA. TGF‐β was only marginally elevated in patients with severe recessive dystrophic EB, while TNF‐α, IFN‐γ and IL‐1β varied inconsistently. Patients reporting itch showed elevations in type 2 immunity (IgE, TSLP, IL4 and/or IL‐31, respectively).ConclusionsOur data suggest a dominant skin barrier and wound healing inflammatory pattern in junctional and dystrophic EB that depends on the wound area and not on the EB type. In EB, itch mediators may be similar to other pruritic disorders.